Dylann Cohn-Emery | Authors


Study Results Appear to Support Larotrectinib Use in NTRK+ Lung Cancer

February 20, 2021

Patients with advanced lung cancer whose tumors harbor an NTRK gene fusion with or without central nervous system metastases were found to have high response rates, durable responses, and extended survival benefit with larotrectinib.

Tivozanib Increased Time Without Symptoms of Disease, Toxicity for Patients with RCC

February 12, 2021

As third- or fourth-line therapy for patients with metastatic RCC, tivozanib hydrochloride demonstrated a statistically significant increased quality-adjusted time without symptoms of disease and toxicity compared with sorafenib.

Phase 3 DETECT III Study Suggests CTC Count to be Possible Biomarker for HER2-Directed Therapy in MBC

December 11, 2020

The study found that favorable outcomes after treatment with lapatinib (Tykerb) were demonstrated by early declines in circulating tumor cell counts (CTCs) in patients with metastatic breast cancer who initially had HER2-negative primary tumors but positive HER2 CTCs.

Belantamab Mafodotin-Based Triplet Elicits High Response Rates, Appears Suitable in Myeloma

December 08, 2020

The ongoing phase 1/2 DREAMM-6 trial found that the addition of belantamab mafodotin to bortezomib and dexamethasone elicited high response rates and a suitable safety profile in patients with relapsed or refractory multiple myeloma.

MEDI-570 Evokes Durable Reponses in Patients with R/R T-Cell Lymphomas

December 08, 2020

A phase 1 trial found that MEDI-570 demonstrated clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.